Anthropic’s Claude Mythos AI model exposed in data leak, revealing advanced cyber capabilities and IPO plans for October 2026. What you need to know.
Revolution Medicines (RVMD) stock analysis: $3.5M insider sale, Truist upgrade to strong-buy, and 94% institutional ownership despite Q4 earnings miss.
Argan (AGX) stock rallied ~10% after Q4 EPS of $3.47 beat estimates by $1.34. Project backlog surged to $2.9B with FY27 guidance exceeding consensus.
Tesla (TSLA) stock dropped 3.59% as Q1 EV sales are projected to fall 28% year-over-year, despite rising gas prices nearing $4 per gallon nationwide.
Dollar General (DG) stock fell 5.8% after naming Jerry Fleeman CEO, despite 3% same-store sales growth and 12% EPS increase. Analysts remain optimistic.
Rubrik (RBRK) stock fell to a 52-week low of $46 as CFO Kiran Kumar Choudary sold $5.9M in shares, despite Q4 earnings beating Wall Street estimates.
Salesforce (CRM) stock declined 30% in 2026, but two directors bought shares in March. Company beat Q4 estimates and authorized $25B buyback program.
Nvidia (NVDA) stock trades at a discount to the S&P 500 for the first time since 2013, despite strong analyst backing and retail investor demand.
Gold prices rose then fell back Friday as Trump extended his Iran deadline to April 6. Bullion remains down over 15% since war started a month ago.
Rocket Pharmaceuticals (RCKT) stock rises after FDA approves KRESLADI, the first gene therapy for severe LAD-I in children, plus a priority review voucher.